| Name | Title | Contact Details |
|---|---|---|
Chris Boult |
Chief Information Officer | Profile |
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.
PanTheryx, Inc., a U.S. medical nutrition company based in Boulder, Colorado, is dedicated to improving global health and quality of life through innovative science.
Great Lakes Drug Development is a Brighton, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pediatrics Plus is a specialized pediatric healthcare provider committed to helping your child succeed in all stages of life through therapy and education.
Deltanoid Pharmaceuticals is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.